南京中医药大学鼓楼临床医学院病理科;中国药科大学基础医学与临床药学院;南京大学医学院附属鼓楼医院病理科;南京大学医学院附属鼓楼医院胰腺外科;
目的 分析肝内胆管癌(ICC)患者的FXYD3表达并探讨其与组织学分型及预后的关系。方法 回顾性提取245例南京鼓楼医院2014年至2024年间行根治性手术切除且术后病理证实为ICC的肿瘤样本。收集患者临床病历资料，术前血清生化指标和随访情况。依据细胞形态和组织结构等将ICC分为大胆管型与小胆管型。采用免疫组化染色法检测FXYD3在ICC组织中的表达情况。Kaplan-Meier法绘制总生存时间(OS)曲线；Cox风险比例回归模型分析影响患者OS的因素。结果 245例患者中FXYD3高表达123例，低表达组122例。在大胆管型ICC中有86.2%(81/94)FXYD3高表达，而小胆管型ICC中有27.8%(42/151)FXYD3高表达，FXYD3表达与ICC组织学分型的差异有统计学意义(χ~2=78.917,P<0.001)。Kaplan-Meier结果显示，FXYD3高表达组患者5年生存率为59.3%(73/123),低于FXYD3低表达组的71.3%(87/122),差异具有统计学意义(P=0.014)。多因素Cox风险比例回归模型结果显示：FXYD3表达是影响肝内胆管癌患者OS的独立因素(HR=1.722,95%CI:1.007～2.945,P=0.047)。结论 FXYD3在大胆管型ICC中高表达且FXYD3高表达是ICC的独立预后风险因素。
| 31 | 0 | 18 |
| 下载次数 | 被引频次 | 阅读次数 |
[ 1 ] Siegel RL,Miller KD,Wagle NS,et al.Cancer statistics,2023[J].CA Cancer J Clin,2023,73(1):17-48.
[ 2 ] Moris D,Palta M,Kim C,et al.Advances in the treatment of intrahepatic cholangiocarcinoma:An overview of the current and future therapeutic landscape for clinicians[J].CA Cancer J Clin,2023,73(2):198-222.
[ 3 ] Kim Y,Moris DP,Zhang X F,et al.Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma:A surveillance,epidemiology,and end results (SEER) analysis[J].J Surg Oncol,2017,116(6):643-650.
[ 4 ] 沈建军，韩惠娟，张丽娜，等.肝内胆管癌中成纤维细胞生长因子受体2表达及临床意义[J].临床肿瘤学杂志，2024,29(11):1089-1094.
[ 5 ] Yap JQ,Seflova J,Sweazey R,et al.FXYD proteins and sodium pump regulatory mechanisms[J].J Gen Physiol,2021,153(4).
[ 6 ] Subrungruanga I,Thawornkunob C,Chawalitchewinkoon-Petmitrc P,et al.Gene expression profiling of intrahepatic cholangiocarcinoma[J].Asian Pac J Cancer Prev,2013,14(1):557-563.
[ 7 ] Li M,Nishimura T,Takeuchi Y,et al.FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters[J/OL].J Clin Invest,2023,133(22)[2024-12-30].https://pubmed.ncbi.nlm.nih.gov/37966117/.
[ 8 ] Yee KX,Lee YC,Nguyen HD,et al.Uncovering the role of FXYD3 as a potential oncogene and early biomarker in pancreatic cancer[J].Am J Cancer Res,2024,14(9):4353-4366.
[ 9 ] Peng X,Gao J,Cai C,et al.LncRNA LINC01503 aggravates the progression of cervical cancer through sponging miR-342-3p to mediate FXYD3 expression[J].Biosci Rep,2020,40(6):BSR20193371.
[10] Morrison BW,Moorman JR,Kowdley GC,et al.Mat-8,a novel phospholemman-like protein expressed in human breast tumors,induces a chloride conductance in Xenopus oocytes[J].J Biol Chem,1995,270(5):2176-2182.
[11] Zhu ZL,Yan BY,Zhang Y,et al.Overexpression of FXYD-3 is involved in the tumorigenesis and development of esophageal squamous cell carcinoma[J].Dis Markers,2013,35(3):195-202.
[12] Zhang Z,Pang ST,Kasper KA,et al.FXYD3:A promising biomarker for urothelial carcinoma[J].Biomark Insights,2011,6:17-26.
[13] Wang LJ,Li QJ,Le Y,et al.Prognostic significance of sodium-potassium ATPase regulator,FXYD3,in human hepatocellular carcinoma[J].Oncol Lett,2018,15(3):3024-3030.
[14] Jin M,Zhang H,Yang J,et al.Expression mode and prognostic value of FXYD family members in colon cancer[J].Aging (Albany NY),2021,13(14):18404-18422.
[15] 中国临床肿瘤学会(CSCO)胆道肿瘤专家委员会.胆道恶性肿瘤精准检测与分子诊断专家共识[J].临床肿瘤学杂志，2024,29(8):797-804.
[16] 《肝内胆管癌病理诊断专家共识(2022版)》编写专家委员会.肝内胆管癌病理诊断专家共识(2022版)[J].中华病理学杂志，2022,51(09):819-827.
[17] 张硕，何鑫涛，毛谅，等.手术后不同分型肝内胆管癌预后危险因素分析 [J].腹部外科，2023,36 (03):204-209.
[18] Ma YS,Wu TM,Qian B,et al.KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation[J].J Cell Mol Med,2021,25(8):4040-4052.
[19] Xue Y,Lai L,Lian W,et al.SOX9/FXYD3/Src axis is critical for ER(+) breast cancer stem cell function[J].Mol Cancer Res,2019,17(1):238-249.
基本信息:
DOI：
中图分类号:R735.7
引用信息:
[1]杨爱华,沈佳楠,周琰等.FXYD3表达与肝内胆管癌患者临床病理特征及预后的关系[J].临床肿瘤学杂志,2025,30(03):220-225.
基金信息:
南京市医学科技发展重大项目(ZDX22001); 南京鼓楼医院临床研究专项面上项目(2022-LCYJ-MS-27)